Form 4: TG Therapeutics Director Yann Echelard Sells 20,000 Shares to Cover Tax Obligations

Director Yann Echelard sold 20,000 shares of TG Therapeutics common stock to cover income tax obligations related to restricted stock vesting.

Summary

• On November 5, 2024, Yann Echelard, a director of TG Therapeutics, sold 20,000 shares of common stock at a price of $24.48 per share.
• The sale was executed to satisfy Mr. Echelard's income tax obligations related to restricted stock.
• Following the transaction, Mr. Echelard beneficially owns 224,098 shares of TG Therapeutics, including restricted common stock that vests over various time periods.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction appears to be a routine sale to cover tax obligations, with no indication of a change in the director's overall confidence in the company.

Industry Context

Sales of shares by company insiders are a common occurrence, often related to personal financial planning or tax obligations. The market typically assesses the context of such sales to determine if they reflect the insider's view of the company's prospects.

Stakeholder Impact

• The sale of shares could have a minor impact on shareholders if it creates downward pressure on the stock price, although the amount is relatively small.

Key Dates